|Videos|August 26, 2020

How COVID-19 Response Impacted Essential Workers

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.

The consequences of SARS-CoV-2 have been particularly felt among wage workers, many of whom have been in contact with people throughout the pandemic due to their employment while young professionals shelter-in-place.

According to Dr. Carlos del Rio, the term health disparity came into widespread use in the United States around 1990. It was intended to highlight health challenges facing socially disadvantaged people and, in particular, members of certain racial and ethnic groups and those who are economically disadvantaged.

The stakes of the conversation around COVID-19, therefore, have become even higher as demographic data emerge to show its sizable impact on those political leaders praised as essential workers.

In this clip, Dr. Martin Kulldorff explains how he believes the COVID-19 response strategy has truly affected the working class in the US.

Kulldorff also answers whether an age-based coronavirus strategy would worsen the pandemic's impact on workers from minority groups.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.